文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-PSMA-617联合聚谷氨酸腮腺保护剂的剂量学与安全性:转移性去势抵抗性前列腺癌患者的初步结果

Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-05-20

这项前瞻性单臂开放标签II期研究在转移性去势抵抗性前列腺癌(mCRPC)患者中评估每周期3.7-5.5 GBq 177Lu-PSMA-617(共4次、间隔8周)联合聚谷氨酸片保护腮腺及甘露醇减少肾脏摄取的安全性、剂量学与早期反应。43例可评估患者中G3血液学毒性2例(4.8%)、G2 8例(19.5%),仅3例(6.9%)出现轻度G1腮腺毒性;17例(40.5%)首周期后PSA下降≥30%。结论认为3.7 GBq/周期方案安全并可产生早期生化和影像学反应,腮腺剂量学提示聚谷氨酸片可能减少腮腺摄取。

要点

  • 43例可评估患者中G3血液学毒性2例(4.8%),G2 8例(19.5%);G1腮腺毒性3例(6.9%),G1肾毒性8例(19.5%)。
  • 首周期后17例(40.5%)PSA下降≥30%,其中13例第二周期后PSA下降>50%。
  • 13例剂量学:腮腺中位吸收剂量0.65 mGy/MBq(范围0.33-2.63),肾脏0.42 mGy/MBq(0.14-0.81)。

核心结论

  • 在晚期、经大量预处理的mCRPC患者中,3.7 GBq/周期的177Lu-PSMA-617是安全的,并在注射后PSMA全身扫描中产生早期生化和影像学反应。
  • 腮腺剂量学提示联合口服聚谷氨酸片可能减少腮腺摄取。

研究设计与样本

  • 前瞻性单臂、开放标签II期研究,于2017年4月在本研究所启动,纳入组织学确诊的晚期mCRPC且既往接受过标准延长生存治疗的患者。
  • 177Lu-PSMA-617注射活度为3.7-5.5 GBq,重复4次、间隔8周;注射前口服聚谷氨酸片作为腮腺保护剂,并静脉输注500 mL 10%甘露醇溶液以减少肾脏摄取。
  • 吸收剂量计算采用MIRD形式(OLINDA/EXM软件);样本量估算采用Bryant and Day设计,同时考虑活度和毒性。
  • 43例合格患者评估毒性和初始反应,其中13例进行剂量学评估。

主要发现

  • 2例(4.8%)患者发生G3血液学毒性,8例(19.5%)发生G2血液学毒性。
  • 仅3例(6.9%)患者出现轻度G1腮腺毒性,8例(19.5%)出现G1肾毒性。
  • 首周期后17例(40.5%)患者PSA下降≥30%,其中13例在第二周期后PSA下降>50%。
  • 中位吸收剂量:腮腺0.65 mGy/MBq(范围0.33-2.63),肾脏0.42 mGy/MBq(范围0.14-0.81),红骨髓0.036 mGy/MBq(范围0.023-0.067),全身0.038 mGy/MBq(范围0.018-0.135)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radioligand therapy (RLT) with 177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate cancer (mCRPC). The present study was designed to define the safety and initial response to a minimal effective injected activity/cycle of 177Lu-PSMA-617 in mCRPC patients. New protective agents for salivary glands and kidney were co-administered and dosimetry was carried out. PATIENTS AND METHODS: A prospective single-arm, open label phase II study on mCRPC was activated at our institute in April 2017. Patients with histologically confirmed advanced mCRPC previously treated with standard life-prolonging agents were enrolled. Folic polyglutamate tablets were orally administered as parotid gland protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake before the injection of 3.7-5.5 GBq of 177Lu-PSMA-617 repeated four times at interval of 8 weeks. The adsorbed dose calculation was performed with MIRD formalism (OLINDA/EXM software). The Bryant and Day design was used to estimate the sample size taking account of both activity and toxicity. RESULTS: Forty-three eligible patients were evaluated for toxicity and initial response. Dosimetry was carried out in 13 patients. Two (4.8%) patients had G3 and 8 (19.5%) had G2 hematological toxicity. Only 3 (6.9%) patients had mild G1 salivary gland toxicity and 8 (19.5%) had G1 renal toxicity. A decrease of ≥ 30% in prostate-specific antigen (PSA) was achieved after the first cycle in 17 (40.5%) patients, of whom 13 had a PSA decline of >50% after the second cycle. The median adsorbed doses were 0.65 mGy/MBq (range 0.33-2.63) for parotid glands, 0.42 mGy/MBq (0.14-0.81) for kidneys, 0.036 mGy/MBq (0.023-0.067) for red marrow, and 0.038 mGy/MBq (0.018-0.135) for the whole body. CONCLUSION: In advanced, heavily pre-treated mCRPC patients, 3.7 GBq/cycle of 177Lu-PSMA-617 was safe and produced early biochemical and imaging responses at PSMA whole-body scan post injection. Dosimetry of salivary glands suggests that the co-administration of polyglutamate tablets may reduce salivary gland uptake. CLINICAL TRIAL REGISTRATION: EU Clinical Trials Register No.: 2016-002732-32; NCT03454750. Collection and assembly of data: April 2017 and February 2019.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Paganelli G, Sarnelli A, Severi S, et al. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32430583. doi:10.1007/s00259-020-04856-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。